Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors.
about
A generic system for the expression and purification of soluble and stable influenza neuraminidaseEntry of parainfluenza virus into cells as a target for interrupting childhood respiratory diseaseStructural and Functional Basis of Resistance to Neuraminidase Inhibitors of Influenza B VirusesCharacterization of two distinct neuraminidases from avian-origin human-infecting H7N9 influenza virusesRisk of resistant avian influenza A virus in wild waterfowl as a result of environmental release of oseltamivirInfluenza neuraminidase inhibitors: antiviral action and mechanisms of resistanceThe anti-influenza virus agent 4-GU-DANA (zanamivir) inhibits cell fusion mediated by human parainfluenza virus and influenza virus HA.Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071.Human-like receptor specificity does not affect the neuraminidase-inhibitor susceptibility of H5N1 influenza virusesTriple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virusResistance mutation R292K is induced in influenza A(H6N2) virus by exposure of infected mallards to low levels of oseltamivirRescue of a H3N2 influenza virus containing a deficient neuraminidase protein by a hemagglutinin with a low receptor-binding affinityCharacterization of H7N9 influenza A viruses isolated from humans.Evolutionary interactions between haemagglutinin and neuraminidase in avian influenza.An overview of the characteristics of the novel avian influenza A H7N9 virus in humans.Antiviral strategies for pandemic and seasonal influenzaNeuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir.In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675.Combining crystallographic information and an aspherical-atom data bank in the evaluation of the electrostatic interaction energy in an enzyme-substrate complex: influenza neuraminidase inhibitionInfluenza A viruses lacking sialidase activity can undergo multiple cycles of replication in cell culture, eggs, or mice.Balanced hemagglutinin and neuraminidase activities are critical for efficient replication of influenza A virus.A single amino acid alteration in the human parainfluenza virus type 3 hemagglutinin-neuraminidase glycoprotein confers resistance to the inhibitory effects of zanamivir on receptor binding and neuraminidase activity.Human parainfluenza virus type 3 HN-receptor interaction: effect of 4-guanidino-Neu5Ac2en on a neuraminidase-deficient variant.Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies.Real time enzyme inhibition assays provide insights into differences in binding of neuraminidase inhibitors to wild type and mutant influenza virusesPhenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181.Epidemiological and viral genome characteristics of the first human H7N9 influenza infection in Guangdong Province, ChinaIdentification of novel compounds against an R294K substitution of influenza A (H7N9) virus using ensemble based drug virtual screeningImportance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza virusesClinical, epidemiological and virological characteristics of the first detected human case of avian influenza A(H5N6) virusThe TLR4 antagonist Eritoran protects mice from lethal influenza infection.Towards a better understanding of the novel avian-origin H7N9 influenza A virus in ChinaResistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population.Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase.R292K substitution and drug susceptibility of influenza A(H7N9) viruses.Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility.The neuraminidase inhibitor oseltamivir is effective against A/Anhui/1/2013 (H7N9) influenza virus in a mouse model of acute respiratory distress syndrome.Emergence of G186D mutation in the presence of R292K mutation in an immunocompromised child infected with influenza A/H3N2 virus, treated with oseltamivir.Discovery of potential drugs for human-infecting H7N9 virus containing R294K mutation.
P2860
Q21091069-ABA9DC79-807C-4FA6-ACB6-BA01F2DB2C27Q24530163-CA4EF0AB-EDA7-4D0D-ADB8-89E5C5D401BCQ27663966-F30360BF-6A15-47C5-90BD-DD9B4C34E4FAQ27680477-0E23D603-0011-4A4B-97DC-A664EB97A307Q28066861-4A7D04F4-4858-4128-8108-19A66894A564Q28282405-2DAB1A0A-BC97-4D11-A503-38681DE10C53Q28344907-1D5BC44D-FA10-405C-B5DB-23E48AD7D815Q28364114-E4F83947-19F0-42EA-8A68-B328F5B6E7FCQ28369317-5F5B7F6F-F7C9-4321-866F-4A96E073736FQ28472513-F080CED3-9998-48D0-9D9C-D3761344F4B2Q28478637-05459EAA-97CD-47AE-951F-CE58DB6A972FQ28535274-CE0B931B-77BF-4900-912D-3534C01E4F40Q28730182-2D514CA7-9BBF-43FC-8A2E-76C3D676F858Q30352001-1D3F98AF-75CB-48EB-B8AB-7961BCD625A1Q30354224-E1A1576C-C4C8-4163-BB2B-8E5759D82D8FQ30372931-9385EE38-FB6B-4464-9D58-AB7B96996DC8Q30408116-BA20CCE2-96F8-4C3C-865F-ECE251F98A13Q30452889-ED663E4F-1EE5-40BC-BF90-C1A94A1CC536Q30453278-E4F78425-FCA0-4BA3-AADF-79CBBFCC9FEEQ33434347-B4580975-446C-4B25-BD1E-D855B7B808E6Q33787108-306F280F-EBC7-425F-8B49-3207D953D952Q33806746-DA082A65-C28B-494B-BF2A-CB3008C4CE7CQ33842791-CF7BCF2B-F021-4803-90CD-F38E13D18C37Q33852786-3B2E6663-EF5B-4841-BBEC-A333224D7A78Q33978456-91F0DC55-208D-4ED9-8A39-D37E05CB0EFDQ33999885-AC9B2E8A-96A9-4A41-88DA-9F3F4B6F5448Q34405859-B9CB6482-4754-4B9A-AD48-A9D9EF5A7A16Q34814431-18009FA3-877D-4714-9D63-DA0837274F94Q34942905-6049E180-BED3-46EE-9EE1-828360A31A9EQ35024169-24DD9B82-C58C-43FB-BEC7-396C5BB028EFQ36862609-8CDBCF9A-9A1E-4EE2-8007-D576B95D3843Q37051987-3906086B-4EF8-442F-9BCC-F060FDD95378Q37054816-E6473004-A706-4F4E-8CB4-8F84EC7BA7A8Q37074496-E44D4E58-8D07-43CD-AF21-E3D93B3890F7Q37169942-90B51453-28FE-4E2B-9E4D-8B18CE5339D6Q37262432-75C7EF90-F305-448B-921F-AC367A8D4FC1Q37394266-85C61324-E983-4111-A00B-BF0CEA88DEE0Q37696588-9995D91B-7278-4FD2-9071-B6B05BB5D92FQ37713714-CE15EE32-1D61-4960-8A28-C61852394037Q39079415-4FFB1D2D-2C58-4A53-8C5E-134FC473B3CB
P2860
Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Mutations in a conserved resid ...... Neu5Ac2en-derived inhibitors.
@en
Mutations in a conserved resid ...... Neu5Ac2en-derived inhibitors.
@nl
type
label
Mutations in a conserved resid ...... Neu5Ac2en-derived inhibitors.
@en
Mutations in a conserved resid ...... Neu5Ac2en-derived inhibitors.
@nl
prefLabel
Mutations in a conserved resid ...... Neu5Ac2en-derived inhibitors.
@en
Mutations in a conserved resid ...... Neu5Ac2en-derived inhibitors.
@nl
P2093
P2860
P1433
P1476
Mutations in a conserved resid ...... Neu5Ac2en-derived inhibitors.
@en
P2093
A Sahasrabudhe
J L McKimm-Breschkin
J N Varghese
M McDonald
P M Colman
R C Bethell
P2860
P304
P407
P577
1998-03-01T00:00:00Z